Skip to main content

Table 5 Association between MMP2/9 overexpression and clinicopathological features in breast cancer patients

From: Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

Clinicopathological feature MMP2 MMP9
No. of patients I2 (%) Model Pooled OR (95%CI) P No. of patients I2 (%) Model Pooled OR (95%CI) P
Tumor size (> 2 cm vs ≤2 cm) 1254 48.4 R 1.17 (0.78–1.75) 0.448 3005 0 F 1.32 (1.13–1.54) < 0.001
Tumor size (> 5 cm vs ≤5 cm) 1286 15.9 F 1.12 (0.76–1.64) 0.568 924 0 F 2.02 (1.28–3.17) 0.002
Lymph node status (+ vs -) 1606 40.3 R 1.22 (0.88–1.70) 0.225 1945 77.1 R 2.90 (1.86–4.53) < 0.001
Distant metastasis (+ vs -) 219 22.0 F 2.69 (1.35–5.39) 0.005
ER (+ vs -) 1784 47.1 R 0.82 (0.57–1.18) 0.290 1975 58.2 R 1.00 (0.71–1.39) 0.990
PR (+ vs -) 1660 5.7 F 1.07 (0.85–1.35) 0.545 1876 55.2 R 1.00 (0.73–1.38) 0.991
HER2 (+ vs -) 361 64.8 R 1.28 (0.49–3.37) 0.612 1007 0 F 1.41 (1.05–1.90) 0.021
TNM stage (III-IV vs I-II) 666 28.0 F 2.09 (1.36–3.21) 0.001 2419 70.7 R 2.00 (1.26–3.19) 0.004
Grade (2–3 vs 1) 1437 0 F 2.11 (1.55–2.88) < 0.001 2051 61.9 R 1.55 (0.91–2.62) 0.107
Grade (3 vs 1–2) 1089 0 F 1.53 (1.14–2.06) 0.005 2609 48.4 R 1.77 (1.32–2.36) < 0.001
  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, F fixed effect model, R random effect model, OR odds ratio
  2. +: positive; −: negative